Lili Ren1,2, Guohui Fan3,4, Wenjuan Wu5, Li Guo1,2, Yeming Wang4,6, Xia Li5, Conghui Wang1, Xiaoying Gu3,4, Caihong Li5, Ying Wang1, Geng Wang1, Fei Zhou4,6, Zhibo Liu4,6, Qing Ge5, Yi Zhang4,6, Hui Li4,6, Lulu Zhang1, Jiuyang Xu7, Chen Wang4,6,8, Jianwei Wang1,2, Bin Cao4,6. 1. NHC Key Laboratory of Systems Biology of Pathogens and Christophe Mérieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. 2. Key Laboratory of Respiratory Disease Pathogenomics, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. 3. Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China. 4. Institute of Respiratory Medicine, Chinese Academy of Medical Science, National Clinical Research Center for Respiratory Diseases, National Center for Respiratory Diseases, Beijing, China. 5. Jin Yin-tan Hospital; Wuhan, Hubei Province, China. 6. Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China. 7. Tsinghua University School of Medicine, Beijing, China. 8. Peking Union Medical College, Beijing, China.
Abstract
BACKGROUND: The characteristics of neutralizing antibodies (NAbs) and antibody against major antigen proteins related to clinical outcomes in severe coronavirus disease 2019 (COVID-19) patients were still less known. METHODS: NAbs and antibodies targeting nucleocapsid (N), spike protein (S), and the receptor-binding domain (RBD) in longitudinal plasma samples from the LOTUS China trial were measured by microneutralization assay and enzyme-linked immunosorbent assay (ELISA). Viral load was determined by real-time reverse transcription polymerase chain reaction (RT-PCR). A total of 576 plasma and 576 throat swabs were collected from 191 COVID-19 patients. Antibody titers related to adverse outcome and clinical improvement were analyzed. Multivariable adjusted generalized linear mixed model for random effects were developed. RESULTS: After day 28 post symptoms onset, the rate of antibody positivity reached 100% for RBD-immunoglobulin M (IgM), 97.8% for S-IgM, 100% for N-immunoglobulin G (IgG), 100% for RBD-IgG, 91.1% for N-IgM, and 91.1% for NAbs. The NAbs titers increased over time in both survivors and nonsurvivors and correlated to IgG antibodies against N, S, and RBD, whereas its presence showed no statistical correlation with death. N-IgG (slope -2.11, 95% confidence interval [CI] -3.04 to -1.18, P < .0001), S-IgG (slope -2.44, 95% CI -3.35 to -1.54, P < .0001), and RBD-IgG (slope -1.43, 95% CI -1.98 to -.88, P < .0001) were negatively correlated with viral load. S-IgG titers were lower in nonsurvivors than survivors (P = .020) at week 4 after symptoms onset. CONCLUSIONS: IgM and IgG against N, S, and RBD and NAbs developed in most severe COVID-19 patients and do not correlate clearly with clinical outcomes. The levels of IgG antibodies against N, S, and RBD were related to viral clearance.
BACKGROUND: The characteristics of neutralizing antibodies (NAbs) and antibody against major antigen proteins related to clinical outcomes in severe coronavirus disease 2019 (COVID-19) patients were still less known. METHODS: NAbs and antibodies targeting nucleocapsid (N), spike protein (S), and the receptor-binding domain (RBD) in longitudinal plasma samples from the LOTUS China trial were measured by microneutralization assay and enzyme-linked immunosorbent assay (ELISA). Viral load was determined by real-time reverse transcription polymerase chain reaction (RT-PCR). A total of 576 plasma and 576 throat swabs were collected from 191 COVID-19patients. Antibody titers related to adverse outcome and clinical improvement were analyzed. Multivariable adjusted generalized linear mixed model for random effects were developed. RESULTS: After day 28 post symptoms onset, the rate of antibody positivity reached 100% for RBD-immunoglobulin M (IgM), 97.8% for S-IgM, 100% for N-immunoglobulin G (IgG), 100% for RBD-IgG, 91.1% for N-IgM, and 91.1% for NAbs. The NAbs titers increased over time in both survivors and nonsurvivors and correlated to IgG antibodies against N, S, and RBD, whereas its presence showed no statistical correlation with death. N-IgG (slope -2.11, 95% confidence interval [CI] -3.04 to -1.18, P < .0001), S-IgG (slope -2.44, 95% CI -3.35 to -1.54, P < .0001), and RBD-IgG (slope -1.43, 95% CI -1.98 to -.88, P < .0001) were negatively correlated with viral load. S-IgG titers were lower in nonsurvivors than survivors (P = .020) at week 4 after symptoms onset. CONCLUSIONS: IgM and IgG against N, S, and RBD and NAbs developed in most severe COVID-19patients and do not correlate clearly with clinical outcomes. The levels of IgG antibodies against N, S, and RBD were related to viral clearance.
Authors: Markus Zeitlinger; Birgit C P Koch; Roger Bruggemann; Pieter De Cock; Timothy Felton; Maya Hites; Jennifer Le; Sonia Luque; Alasdair P MacGowan; Deborah J E Marriott; Anouk E Muller; Kristina Nadrah; David L Paterson; Joseph F Standing; João P Telles; Michael Wölfl-Duchek; Michael Thy; Jason A Roberts Journal: Clin Pharmacokinet Date: 2020-10 Impact factor: 6.447
Authors: He S Yang; Sabrina E Racine-Brzostek; Mohsen Karbaschi; Jim Yee; Alicia Dillard; Peter A D Steel; William T Lee; Kathleen A McDonough; Yuqing Qiu; Thomas J Ketas; Erik Francomano; P J Klasse; Layla Hatem; Lars Westblade; Heng Wu; Haode Chen; Robert Zuk; Hong Tan; Roxanne C Girardin; Alan P Dupuis; Anne F Payne; John P Moore; Melissa M Cushing; Amy Chadburn; Zhen Zhao Journal: Biosens Bioelectron Date: 2021-01-20 Impact factor: 12.545
Authors: Jennifer M Sasson; Joseph J Campo; Rebecca M Carpenter; Mary K Young; Arlo Z Randall; Krista Trappl-Kimmons; Amit Oberai; Christopher Hung; Joshua Edgar; Andy A Teng; Jozelyn V Pablo; Xiaowu Liang; Angela Yee; William A Petri; David Camerini Journal: mBio Date: 2021-06-29 Impact factor: 7.867
Authors: David M Smadja; Steven J Mentzer; Michaela Fontenay; Mike A Laffan; Maximilian Ackermann; Julie Helms; Danny Jonigk; Richard Chocron; Gerald B Pier; Nicolas Gendron; Stephanie Pons; Jean-Luc Diehl; Coert Margadant; Coralie Guerin; Elisabeth J M Huijbers; Aurélien Philippe; Nicolas Chapuis; Patrycja Nowak-Sliwinska; Christian Karagiannidis; Olivier Sanchez; Philipp Kümpers; David Skurnik; Anna M Randi; Arjan W Griffioen Journal: Angiogenesis Date: 2021-06-28 Impact factor: 9.596